Bio-Techne Corporation (FRA:TE1)

Market Cap	7.64B -33.4%
Revenue (ttm)	1.04B +1.6%
Net Income	69.04M -48.7%
EPS	0.44 -47.0%
Shares Out	n/a
PE Ratio	110.64
Forward PE	27.62
Dividend	0.28 (0.57%)
Ex-Dividend Date	Feb 13, 2026

Volume	n/a
Average Volume	5
Open	49.00
Previous Close	49.00
Day's Range	48.40 - 49.00
52-Week Range	40.60 - 62.50
Beta	n/a
RSI	35.17
Earnings Date	Feb 4, 2026

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue cultur...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1976
• Employees: 3,100
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: TE1

Financial Performance

In fiscal year 2025, Bio-Techne's revenue was $1.22 billion, an increase of 5.23% compared to the previous year's $1.16 billion. Earnings were $73.36 million, a decrease of -56.35%.

Financial numbers in USD